Pathway Diagnostics has released its patented, second-generation SensiTrop II assay for HIV-infected patients. The product combines the sensitivity of molecular heteroduplex tracking assay technology with molecular sequencing to determine the CCR5 co-receptor tropism status of patients, according to Pathway. It provides clinicians a fast, accurate, sensitive and economical testing alternative to biological HIV tropism assay.